EQUISUL-SDT® (Sulfadiazine/Trimethoprim)

EQUISUL-SDT® is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subsp. zooepidemicus. EQUISUL-SDT® is produced using Aurora Pharmaceutical’s patented drug product formulation. The product demonstrated 20% increased bioavailability over an existing paste product in a pharmacokinetic crossover study.

Product Features

  • Safety was demonstrated in a controlled study in horses at 1X, 3X and 5X the recommended dose for 30 days
  • Low incidence of side effects in controlled safety studies
  • Easy-to-use, apple-f lavored liquid formulation
  • Significantly higher bioavailability on a mg-to-mg basis compared to an approved paste product, based on a pharmacokinetic crossover study

Availability

*Includes draw-off cap

135 mL Bottle — Reorder No: 28000

*280 mL Bottle — Reorder No: 28003

*560 mL Bottle — Reorder No: 28002

900 mL Bottle — Reorder No: 28001

Clicking a link on this page will open a PDF file in a new window.
Equisul-SDT Aurora Pharmaceutical Ad

Equisul-SDT Aurora Pharmaceutical Ad
Equisul-SDT Aurora Pharmaceutical Ad
Equisul-SDT Aurora Pharmaceutical Ad